Pharmacovigilance – News and Features

Study to determine the safety of escalating radiation doses of the BrachySil™ device, with tumor response as a secondary end point.

The study showed in both young and elderly subjects that EVT 101 was well tolerated up to the highest dose tested.

Phase IA clinical trial involves testing of RGN-352, an injectable formulation of Tß4 for potential use in treating acute myocardial infarction patients.

Company’s second most advanced product is progressing to Phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ascites.

The $120 million transaction includes license to Maxygen’s novel biotechnology research platform.

The three-month human pharmacokinetic study is designed to support the ongoing pivotal Phase III clinical trial of Medidur in DME.

Minor genetic differences between individuals change the effect of a common medication, study shows.

France's regulatory agency has authorized the company to increase inecalcitol dosage in its Phase II clinical trial for hormone-refractory prostate cancer.

A new blood test may make it easier to measure and personalize 5-FU dosing for patients undergoing infusion chemotherapy regimens.

PSN602 is an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity.